Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it will present data for its oncology candidate NT219, a first-in-class small molecule, dual-inhibitor of IRS 1/2 and STAT3, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting which takes place April 5-11, 2024, in San Diego, California.
- “The growing body of clinical, biomarker, and preclinical data for NT219 demonstrate its potential not only in the lead indication of recurrent/metastatic squamous cell carcinoma of the head and neck, but also in other solid-tumor cancers.
- These publications at AACR 2024 are a result of the progress made last year both in clinical and preclinical work bringing out NT219’s attributes,” stated Gil Efron, Chief Executive Officer of Purple Biotech.
- “We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.”
Dr Hadas Reuveni, VP Research and Development at Purple Biotech, added, “At AACR 2024 we will present new data related to NT219. - The presented posters will be available on the Publications section of Purple Biotech’s website, following their presentations at the conference.